Bradley Merrill Thompson, Member of the Firm, speaks on “Legal and Regulatory Opportunities to Address Bias and Transparency in Artificial Intelligence/Machine Learning (AI/ML) in Medical Devices,” at the Food and Drug Law Institute (FDLI) Annual Conference: Exploring Advanced Topics in Food and Drug Law.
Al/ML-based technologies have the potential to transform health care through their unique ability to learn from real-world feedback and adapt based on these learnings. However, the data that is used to learn may drive inherent biases. What can FDA and companies do to ensure that AI/ML-enabled products do not reproduce or amplify existing inequalities? Brad and others explore how biases from collection can degrade AI/ML algorithm performance and what tools FDA and companies can use to help combat bias.
For more information and to register, please visit FDLI.org.